Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Zylox-Tonbridge Medical Technology HK$2.56 billion IPO
We advised Zylox-Tonbridge Medical Technology on its IPO and HKEX listing
HUTCHMED HK$4.17 billion IPO and primary listing
The shares are listed on the Hong Kong Stock Exchange
GH Research $184 million IPO
We advised GH Research on the IPO and Nasdaq Listing
Theravance Biopharma $100.5 million follow-on offering
We advised the underwriters on the equity offering
ATAI Life Sciences $258.8 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Century Therapeutics $242.7 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Cyteir Therapeutics $133.2 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Convey Holding Parent $186.7 million IPO
We advised the underwriters on the IPO and NYSE listing
Molecular Partners $64 million IPO
We advised the joint book-running managers and underwriters on the IPO and Nasdaq listing
RAPT Therapeutics $143.7 million follow-on offering
We advised the joint book-running managers on the SEC-registered equity offering